• Janux Therapeutics Announces Pricing of Initial Public Offering

    6 days ago - By San Diego Biotechnology

    LA JOLLA, Calif.--Janux Therapeutics, Inc. , a biopharmaceutical company developing novel T cell engager immunotherapies, today announced the pricing of its initial public offering of 11,400,000 shares of its common stock at a price to the public of $17.00 per share. The gross proceeds to Janux from the offering,...
    Read more ...